These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Psychedelics and music: neuroscience and therapeutic implications. Barrett FS; Preller KH; Kaelen M Int Rev Psychiatry; 2018 Aug; 30(4):350-362. PubMed ID: 30240282 [TBL] [Abstract][Full Text] [Related]
24. History and pharmacology of psychedelic drugs. Taylor WJ Int Z Klin Pharmakol Ther Toxikol; 1971 Aug; 5(1):51-7. PubMed ID: 4936558 [No Abstract] [Full Text] [Related]
25. Psychedelic crossings: American mental health and LSD in the 1970s. Richert L; Dyck E Med Humanit; 2020 Sep; 46(3):184-191. PubMed ID: 31235651 [TBL] [Abstract][Full Text] [Related]
27. The potential of psychedelic medicine - A personal account. Smith DE J Neurol Sci; 2022 Mar; 434():120128. PubMed ID: 34998238 [TBL] [Abstract][Full Text] [Related]
29. Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Winkelman M Curr Drug Abuse Rev; 2014; 7(2):101-16. PubMed ID: 25563446 [TBL] [Abstract][Full Text] [Related]
30. Research ethics aspects of experimentation with LSD on human subjects: a historical and ethical review. Bodnár KJ; Kakuk P Med Health Care Philos; 2019 Jun; 22(2):327-337. PubMed ID: 30327902 [TBL] [Abstract][Full Text] [Related]
31. [Narcotics abuse in adolescents]. Leuner H Nervenarzt; 1971 Jun; 42(6):281-91. PubMed ID: 4931883 [No Abstract] [Full Text] [Related]
32. Psychedelic drugs and creativity. Krippner S J Psychoactive Drugs; 1985; 17(4):235-45. PubMed ID: 4087078 [No Abstract] [Full Text] [Related]
33. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. Mastinu A; Anyanwu M; Carone M; Abate G; Bonini SA; Peron G; Tirelli E; Pucci M; Ribaudo G; Oselladore E; Premoli M; Gianoncelli A; Uberti DL; Memo M Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674849 [TBL] [Abstract][Full Text] [Related]
34. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer. Barnett BS; Greer GR J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406 [TBL] [Abstract][Full Text] [Related]
35. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Garcia-Romeu A; Richards WA Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079 [TBL] [Abstract][Full Text] [Related]
36. Dark Classics in Chemical Neuroscience: Mescaline. Cassels BK; Sáez-Briones P ACS Chem Neurosci; 2018 Oct; 9(10):2448-2458. PubMed ID: 29847089 [TBL] [Abstract][Full Text] [Related]
37. The effects of lysergic acid diethylamide and mescaline-derived hallucinogens on sensory-integrative function: tactile startle. Geyer MA; Petersen LR; Rose GJ; Horwitt DD; Light RK; Adams LM; Zook JA; Hawkins RL; Mandell AJ J Pharmacol Exp Ther; 1978 Dec; 207(3):837-47. PubMed ID: 731434 [TBL] [Abstract][Full Text] [Related]
38. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. Barnett BS; Ziegler K; Doblin R; Carlo AD J Psychopharmacol; 2022 Oct; 36(10):1118-1128. PubMed ID: 35971893 [TBL] [Abstract][Full Text] [Related]
39. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. Barnett BS; Parker SE; Weleff J Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734 [TBL] [Abstract][Full Text] [Related]
40. Psychedelics: Where we are now, why we got here, what we must do. Belouin SJ; Henningfield JE Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]